Cullinan Therapeutics, Inc. Common Stock — Grafico, Quotazione e Notizie (NASDAQ:CGEM) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Market Capitalization 868.55 M
Employee 109
Founded 2016
CEO N/A
Website www.cullinantherapeutics.com
Headquarter Delaware, United States
FIGI BBG00HW2DGQ4
Industry Technology

Ricavi totali

Utile netto

Utile base per azione (EPS base)

Debito totale

Liquidità libera

Disponibilità liquide e mezzi equivalenti

868.55 M Capitalizzazione di mercato

Rapporto prezzo/utili

—

Rapporto prezzo/fatturato

—

Notizie

Clear Street conferma il rating su Cullinan Oncology dopo l’accordo Gilead

Stifel alza il target su Cullinan Oncology per progressi autoimmuni

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

Guggenheim avvia la copertura di Cullinan Oncology con rating Buy e target di $30

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Cullinan Therapeutics pianifica la pubblicazione di dati per programmi chiave autoimmuni